Hoffmann-La Roche GO28667, A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients with Chronic Lympocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared with Bendamustine Plus Rituximab

Cancer - Leukemia

At least 18 years of age; diagnosis of chronic lymphocytic leukemia which is relapsed or refractory; previously treated with 1-3 lines of therapy including at least one standard chemotherapy-containing regimen.

Tiffany Pearce